Iridium-electrode inhaled Nitric Oxide generator for treatment of hypoxic respiratory failure in neonates
Iridium-electrode inhaled Nitric Oxide generator for treatment of hypoxic respiratory failure in neonates
批准号:
9199502
负责人:
Philip E Silkoff
金额:
$75.45万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2018-05-31
关键词:
AcuteAdultAirAmericanAnesthesia proceduresAnimalsBreathingCatheterizationChildhoodClinicalClinical ResearchClinical TrialsComplexComputer softwareCustomDataDevelopmentDevicesElectrodesEnsureEtiologyFactor AnalysisGasesGeneral HospitalsGoalsGrantHeart failureHospitalsHumanHypoxiaInfantInhalation TherapyInterventionInterviewIridiumLaboratoriesLifeLiteratureLungMapsMarketingMassachusettsMechanical VentilatorsMedicalMedical DeviceMedicineModelingMonitorNational Heart, Lung, and Blood InstituteNeonatal Intensive Care UnitsNitric OxideNitrogen DioxideOxygenPatientsPenetrationPhasePriceProbabilityPulmonary HypertensionReadinessReportingResearchRespiratory FailureSafetySeriesSmall Business Innovation Research GrantSystemTechnologyTestingTherapeutic EquivalencyTimeUnited States Food and Drug AdministrationVasodilationVasodilator AgentsVisitWorkabstractingbasecostdesignelectric impedanceexperiencehealthy volunteerinhaled nitric oxideneonatenovelparticleprogramsprototypepulmonary arterial hypertensionrespiratorysafety testingsensorsuccessuptakeusabilityuser-friendly
中文摘要
摘要
英文摘要
Abstract
We propose to develop a medical device building on an existing clinical
prototype that generates medical grade nitric oxide (NO) from air for inhalation.
An iridium-electrode inhaled NO generator will supersede existing devices which
utilize NO cylinder supply chains and complex bedside administration systems,
and vastly increase worldwide access to this lifesaving pediatric selective
pulmonary vasodilator.
Inhaled NO produces pulmonary vasodilation without systemic
vasodilation, which is a significant issue with other currently available therapies.
In December 1999, the US Food and Drug Administration (FDA), approved
inhaled NO for the treatment of hypoxic term or near-term infants with hypoxic
respiratory failure (HRF) since which time inhaled NO has been a life-saving
intervention for hospitalized infants to treat acute pulmonary hypertension.
Our collaborators in the Zapol lab at MGH recently reported on data
obtained from testing a 110V AC-powered bedside NO generating device in a
lamb model of pulmonary artery hypertension (PAH). This prototype was
subsequently tested in a human proof of concept (POC) trial in 6 healthy
volunteers and to date 5 patients with PAH in the MGH catheterization lab. Third
Pole and the Zapol lab have commenced work under NHLBI B-BIC/NCAI grant
#U54HL119145 to optimize the electrode design of an NO generator for use with
mechanical ventilators and anesthesia machines.
We will develop an iridium-electrode NO generator with expert clinician
input under FDA design controls which will serve as a basis for clinical
bioequivalence studies anticipated to be required for regulatory approval.
Development in the academic setting has not yet been conducted under formal
FDA design controls, a requirement for obtaining IDE status and entering broader
clinical trials. An iridium-electrode inhaled NO generator, with optimal materials
and design will enable worldwide provision of NO inhalation therapy for infants
with HRF.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Iridium-electrode inhaled Nitric Oxide generator for treatment of hypoxic respiratory failure in neonates
-
批准号:9752063
-
项目类别:
-
资助金额:$99.95万
-
财政年份:2016
-
负责人:Philip E Silkoff
-
依托单位:
Iridium-electrode inhaled Nitric Oxide generator for treatment of hypoxic respiratory failure in neonates
-
批准号:9335961
-
项目类别:
-
资助金额:$74.45万
-
财政年份:2016
-
负责人:Philip E Silkoff
-
依托单位:
海外基金